Trump's renewed broadsides on drug pricing didn't even dent biopharma this time
Late Monday President Donald Trump took his second shot at Merck CEO Ken Frazier. Clearly still rankled by Frazier’s decision to resign from Trump’s manufacturing council, the president Tweeted:
.@Merck Pharma is a leader in higher & higher drug prices while at the same time taking jobs out of the U.S. Bring jobs back & LOWER PRICES!
— Donald J. Trump (@realDonaldTrump) August 14, 2017
Trump buckled under pressure and took a direct swipe at right-wing extremists on Monday, a delayed reaction that boiled into a viral discussion over the president and his reluctance to single out the KKK and others from the bully pulpit of the presidency. But none of it satisfied the president’s critics. The big question for biopharma now was whether Trump, who’s gone dead silent on the issue of drug pricing — until yesterday — would rip back into the industry after being angered by Frazier, one of the few black CEOs in the Fortune 500.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.